Abstract Acute encephalitis caused by the Japanese encephalitis virus (JEV) represents a growing epidemic and is a cause for concern in Southeast Asia. JEV is transmitted to humans through the bite of the Culicine mosquito species. The virus genome comprising of an RNA strand also encodes the envelope protein (E) which surrounds the virus. The E protein aids in fusion of virus with the cellular membrane of the host cell with the help of three structurally distinct domains (DI, DII, DIII) that are connected by flexible hinge regions. Of these domains, DIII (JEV-DIII) has been reported to interact with the cellular membrane, aid viral entry and viral replication. Hence JEV-DIII has the potential to be an antigen that can provide immune protection to a JEV infection. In this study, we describe the cloning and expression of DIII of GP-78, a virulent strain of JEV prevalent in India. Our data clearly shows that JEV-DIII expressed from pVAC1 in HEK293T cells is membrane targeted. To our knowledge, this is the first demonstration of a recombinant construct that may block JEV entry into the cells and/or evoke specific antibodies against JEV. Future studies will reveal if our construct will elicit significant immune responses which will alleviate or ameliorate the pro-inflammatory responses induced by JEV.
Japanese encephalitis along with Dengue fever, Yellow fever, West Nile encephalitis are diseases caused by viruses belonging to the flaviviridae family. JEV is predominantly transmitted to humans by the Culicine mosquitoes, of which Culex tritaeniorhyncus, Culex gelidus are the principal vectors [4, 17] . More than 3 billion people are now living and over 70 million children are born in JE endemic regions each year [4, 34] .
JEV is a small, enveloped icosahedral virus, in which the single-stranded, positive-sense RNA viral genome (*11 kb) consists of single open reading frame (ORF) encoding a polyprotein that is processed into three structural (core-C, premembrane-pRM, and envelope-E) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins, flanked by 5 0 -and 3 0 -nontranslated regions (NTRs) [6] . The viral RNA is complexed to multiple copies of the capsid protein forming the nucleocapsid assembly [20] . The spherical nucleocapsid is surrounded by the envelope (E) protein, which is glycosylated. In mature virions, the E glycoproteins are arranged in 90 homodimers with sets of three E head-to-tail homodimers that lie in 30 rafts and form a her-ringbone pattern [16] .
Flaviviruses like JEV utilize clathrin-mediated endocytosis for cell entry [14, 28] . The E protein plays important role in viral attachment, membrane fusion, and entry of virus. It is a major structural protein that contains numerous neutralization epitopes, which mediates attachment of virus to the host cells. Both poly and monoclonal antibodies inhibit viral attachment to host cells or block viral penetration by binding to these epitopes. For example, it contains one putative N linked glycosylation site at N154 or a putative receptor-binding domain that induces the host immune response. Immunogenicity of DNA vaccine synthesizing the two forms of E protein i.e. secretory and membrane anchored was tested in mice using intradermal and intramuscular delivery. Approximately 60% protection was observed to be provided by the vaccine irrespective of the route of vaccine delivery and form of E protein [7, 18] . In order to localize the neutralization antigenic site in the linear amino acid sequence of JEV E protein, Mason et al. [25] synthesized the small fragments of the E protein as trpE fusion proteins in E. coli. They found that E protein segment containing residues 303-396 was the shortest sequence capable of reacting with various JEV-neutralizing monoclonal anti-bodies [15, 31] . Several authors have used the Envelope protein of viruses as the immune response provoking agent (for examples, see [10, 27] ).
The E protein ectodomain has three structurally distinct domains (DI, DII, DIII) that are connected by flexible hinge regions [30] . The E protein exits as a homodimer in which each monomer has three b-barrel domains viz. domain I, domain II and domain III. Among these domains, Domain III is an immunoglobulin (Ig)-like domain that is thought to contain the putative receptor-binding sites 32-37 [26] . Negatively charged glycoaminoglycans, such as heparan sulfate, which are abundantly ex-pressed on numerous cell types are utilized as low-affinity attachment factors by several flavi-viruses. These interactions serve to concentrate the virus at the cell surface and are mediated by domain DIII of the E glycoprotein. DIII also plays a vital role in internalization of the virus and docking with cellular membranes to aid viral replication. JEV-DIII has been shown to be both immune reactive and immune response provoking by several authors [2, 19, 33] . Thus we hypothesized that the DIII could be a potential antigen for future vaccine development and we studied the localization of DIII in mammalian cells. In the present study, we report the cloning and expression of Domain III (DIII) of the Envelope protein (E) of GP-78, a virulent strain of JEV prevalent in India in mammalian cells.
The WHO prequalified JEV vaccine, SA-14-14-2 is a live attenuated virus which does not cross the blood-brain barrier but evokes similar immune responses in the host. SA-14-14-2 has three major problems: (1) It is not suited for infant's below 1 years of age, (2) There is a requirement for booster doses to achieve sustainable immunity and (3) Patient is to be kept under observation for 48 h to 1 week after administration of vaccine as many side effects are observed [3, 11, 13] .
In this regard, DNA vaccines provide an alternative to conventional vaccines and have achieved success against several families of viruses such as HIV [32] HBV [9] , Influenza virus etc. [23] . DNA vaccines are plasmids encoding a gene of interest that can be propagated in bacteria so that the gene of interest is expressed in mammalian cells (by means of a strong viral promoter) and provokes a good immune response conferring immunity against the particular pathogen [8, 21] . This line of approach is also emerging for vaccine development against JEV and the envelope protein (E) has been the target of many studies.
Given that JEV-DIII has been shown to be both immune reactive and immune response provoking by several authors [2, 19, 33] . Thus we hypothesized that the DIII could be a potential antigen for future vaccine development and we studied the localization of DIII in mammalian cells. In the present study, we report the cloning and expression of Domain III (DIII) of the Envelope protein (E) of GP-78, a virulent strain of JEV prevalent in India in mammalian cells.
The JEV strain GP78 (JEV-GP78), which was responsible for the epidemic in Gorakhpur, India in 1978, is still the most prevalent strain in India and was kindly provided by Dr. T.N. Dhole, Sanjay Gandhi Post-Graduate Institute (SGPGI), Lucknow, India. Virus was amplified by injecting quarantined suckling mice with the virulent strain (0.1 ml) of JEV intracerebrally and observation of associated morbidity in mice such as hind limb paralysis, hunching and ruffling. Post-observation of symptoms, mice were sacrificed, brains harvested and homogenized in phosphate buffered saline (PBS). The homogenates were centrifuged at 5000 rpm for 10 min at 4°C and the supernatant was used as the viral stock for further experiments. All viral stocks were stored at -80°C until further use.
The envelope (E) protein of the SA-14-14-2 genome (Genbank number U14163.1), spans from 978-2478 bp consisting of 500 amino acids of the viral protein of which 111 amino acids, from 291 to 402 has been designated as Domain III of the E protein (JEV-DIII) [19] . The JEV-DIII peptide corresponds to a RNA/DNA to a fragment of length 333 bp (1851-2184 bp, see Supp Fig 1) . We chose to clone and express DIII because (1) recombinant expression of DIII as an isolated peptide, would compete with JEV and prevent cellular entry of the virus and (2) ectopic expression of DIII may also become antigenic and provoke an immune response against JEV in vivo. However since the vaccine strain of JEV, SA-14-14-2 is a mutated virus which does not enter the brain, we cloned and expressed DIII of GP-78 (the amino acid numbers are same to that mentioned for SA-14-14-2). To aid cloning into a variety of plasmids, JEV-DIII was first cloned into a cloning vector pJET-III as per manufacturer's instructions by blunt ligation. Ligation products were transformed into E. coli (DH5a). Colonies were screened for the presence of the recombinant pJET-JEV-DIII by colony PCR (Supp Fig  1A) . Plasmid DNA was isolated and the purified plasmids were sent for sequencing using both forward and reverse primers. Sequencing results indicated the presence of positive clones containing recombinant pJET-JEV-DIII (Supp Fig 1B) . Translation of the sequencing results and alignment reveals the cloned DIII contains G rather than E at position 88 similar to that of GP78 but not similar to that of SA-14-14-2 (Supp 1C). pVAC1 (InvivoGen) is a plasmid designed for preparation of DNA vaccines. The vector was designed so that any protein expressed from this plasmid is expressed at the cell membrane because of the presence of a glycophosphatidylinositol (GPI) anchoring domain of human PLAP which acts as membrane localization signal [1] . The PLAP signal peptide consists of the C terminal amino acids of PLAP which is bound to the membrane by a phosphatidylinositol anchor and is cleaved off during signaling [1] . The PLAP signal peptide has also been used by other authors to enable membrane localization and secretion of peptides [5] .
Further pVAC1 is also a muscle targeting vector as the backbone and comparison of routes of delivery of plasmids into rodents or humans have revealed that intramuscular delivery of the DNA yield the highest titer values [24] . In addition, vectors encoding IL-2 had enhanced humoral and cellular immune responses to an exogenous antigen [12, 22, 29] . Thus we expect that the PLAP and the IL-2 signals in pVAC1 will target and anchor the JEV domain III to the muscle membrane for immune processing, assist secretion of the antigen and will provoke a humoral response.
To clone JEV-DIII into pVAC1, the recombinant pJET-JEV-DIII vector was digested with EcoR1 and BamH1, the fragment isolated and ligated with a EcoR1-BamH1 digested pVAC1 to yield the recombinant pVAC1-JEV-DIII and positive colonies using pVAC1 specific primers (Supp Fig 2B) .
After confirmation by sequencing, recombinant pVAC1 containing JEV-DIII-GFP was isolated and transfected into HEK293T cells (Fig. 1a, b) . As can be seen DIII localizes to the membranes of HEK cells. Our data clearly shows that JEV-DIII expressed from pVAC1 in HEK293T cells is membrane targeted (Fig. 1b) . To our knowledge, our study is the first such attempt to create a recombinant construct which may through virtue of DIII expression on the membrane prevent JEV entry and could also provoke an antibody response. This is not known at present and has to be investigated. 
